NEW YORK, March 13 – Xanthon of Research Triangle Park, NC, said Tuesday it would release its electrochemical DNA, RNA, and protein detection and analysis system for beta testing later this year, adding that the technology would offer potential users an alternative to reverse transcriptase PCR.
“Reverse transcriptase PCR is very labor intensive. With our system you don’t have to purify or amplify the sample and there’s no chemical label,” said Susan Taylor, director of corporate communications for Xanthon. “The fewer steps in the protocol, the more integrity you have in your results.”
Taylor said that the Xanthon Xpression Analysis System, which is built on a 96 well-plate format and has seven electrodes that can generate 672 data points in under five minutes, would be available for commercialization in the first quarter of next year.
Taylor also said that Colorado MEDtech had agreed to manufacture the analysis instrument that comes with the system. She would not disclose the terms of the multi-year deal, but said that it was partially dependent on the volume of instruments sold.
Colorado MEDtech, of Boulder, Colo., manufactures electronic and electromechanical medical devices and instrumentation.
“We’re not geared for manufacturing electronic instruments, but that’s their specialty,” Taylor said.
In addition to the expression analysis system, Xanthon, a 50-person company that has raised $23 million in venture capital, is also planning launch a SNP analysis system as well as a proteomics analysis system.